Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms
Study Details
Study Description
Brief Summary
A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Dr. Bin Wang developed the investigational vaccine used in this clinical trial and designed the trial protocol.For patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma tumor who have disease progression with first line chemotherapy. Single or multiple doses of personalized mRNA tumor vaccine encoding neoantigen will be given to observe the safety and efficacy the mRNA tumor vaccine.
Primary objectives:
Determine the safety, tolerability and cytokinetics of the personalized mRNA tumor vaccine in patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma.
Secondary objectives:
Make a preliminary evaluation on the efficacy of personalized mRNA tumor vaccine in patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma with the following parameters:
Time of tumor progression (TTP);
Disease Control Rate (DCR);
Objective Remission Rate (ORR);
Overall Survival (OS).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Personalized mRNA Tumor Vaccine Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma |
Biological: Personalized mRNA Tumor Vaccine
subcutaneous injection with personalized mRNA tumor vaccine at least four times
|
Outcome Measures
Primary Outcome Measures
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [24 weeks]
During the trial conduction, especially within the 24 weeks of treatment phase when mRNA tumor Vaccine administered, all adverse events (including laboratory abnormality and clinical events) will be closely monitored, and all ≥ grade 3 adverse events per CTCAE (v 3.0) will be recorded, including but not limited to the toxicities potentially suspected to relate to injection procedures and/or mRNA Tumor Vaccine therapy as listed below: Fever Chills Nausea, vomiting and other gastrointestinal symptoms Fatigue Hypotension Respiratory distress Tumor lysis syndrome Neutropenia, thrombocytopenia Liver and kidney dysfunction
Secondary Outcome Measures
- Disease Control Rate of Personalized mRNA Tumor Vaccine [1.5 years]
Disease Control Rate (DCR)
- Progression-free Survival of Personalized mRNA Tumor Vaccine [2 years]
Progression-free Survival (PFS)
- Time to Tumor Progression of Personalized mRNA Tumor Vaccine [2 years]
Time to Tumor Progression (TTP)
- Overall Survival of Personalized mRNA Tumor Vaccine [3 years]
Overall Survival (OS)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients aged 18 - 75 with pathologically confirmed advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma.
-
Patients with advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma who have disease progression with first line chemotherapy. (1) Failure of treatment is defined as disease progression, recurrence or metastatic disease, or intolerable toxicities occurred after treatment. (2) Each line of treatment during the period of disease progression includes one or more chemotherapy drugs which are administered for not less than one cycle or even longer. Neoadjuvant/adjuvant therapy can be applied at an earlier stage of treatment. If patient has developed recurrence or metastatic disease within 24 weeks of neoadjuvant/adjuvant therapy, it is considered as one line of systemic chemotherapy. (3) Therapies that can be performed at an earlier stage are chemotherapy in conjunction with molecular targeted drugs.
-
Expected survival after first dose of study drug > 24 weeks.
-
At least one measurable lesion (≥ 10 mm) for imaging assessment.
-
ECOG scores 0 - 1.
-
Fresh pathological tissue specimens can be obtained
-
White blood cells (WBCs) ≥ 2.5×10^9/L
-
Platelets (PLT) ≥ 100×10^9/L
-
Hemoglobin, Blood (Hb) ≥ 9.0 g/dL
-
MID ≥ 1.5×10^9/L
-
Lymphocyte (LY) ≥ 0.47×10^9/L
-
LY% ≥ 15%
-
Serum albumin (Alb) ≥ 30 g/L
-
Serum lipase (LPS) and serum amylase < 1.5 ULN
-
Serum creatinine ≤ 1.5 ULN
-
Alanine aminotransferase (ALT) ≤ 2.5 ULN
-
Aspartate aminotransferase (AST) ≤ 2.5 ULN
-
If osseous metastasis or liver metastasis is developed and alkaline phosphatase • (ALP) > 2.5 ULN, ALT and AST < 1.5 ULN.
-
Serum total bilirubin (TBIL) ≤ 1.5 ULN
-
Prothrombin Time (PT): International Normalized Ratio (INR) < 1.7.
- PT < (ULN + 4) s
All test results should be within their normal ranges, and the patient is not receiving continuous supportive care.
Exclusion Criteria:
Patients with any of the following conditions are not eligible for the study.
-
Pregnant or lactating women.
-
HIV positive, HCV positive, HBV DNA copies ≥ 10^3.
-
Uncontrolled active infection.
-
Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
-
Allergic to immunotherapies and related drugs.
-
Untreated brain metastases or having symptoms of brain metastases.
-
Metastases to the lung: central tumor or multiple metastases.
-
Patients with heart disease for which treatment is needed or with poorly controlled hypertension.
-
Patients with unstable or active peptic ulcer or with alimentary tract hemorrhage.
-
Patients with previous organ transplantation or in preparation for organ transplantation.
-
Patients have undertaken major surgeries or have been badly injured 4 weeks before the study (blood collection), or will undertake major surgeries during the study.
-
The judgment of investigators that the patient is not able to or not willing to follow the instructions of the protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Changhai Hospital | Shanghai | Shanghai | China |
Sponsors and Collaborators
- Changhai Hospital
- Stemirna Therapeutics
Investigators
- Study Director: Xianbao Zhan, Dr., Chanhai hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CHO-01002